Galapagos and Celera Genomics sign gene function analysis agreement
Galapagos announced that it has entered into a services agreement with Celera Genomics Group, an Applera Corporation business. Under the agreement, Galapagos' services division Galadeno will provide technology and adenoviral reagents enabling Celera to analyze gene function in human cells and validate potential drug targets. Galadeno will receive payments related to its services and technology.
Under the terms of the agreement, Galadeno will construct recombinant adenoviruses harboring genes selected by Celera. These custom-made viruses will be used to introduce the genes into various cell types to evaluate their function within biological pathways.
Other news from the department business & finance
These products might interest you

Blotting standards and reagents by Cytiva
Western blotting standards and reagents
Blotting the course to effective detection of proteins from sample preparation to analysis

Micro-Dx™ CE IVD by Molzym
Fully automated from sample to PCR analysis
Rapid identification of bacteria and fungi without time-consuming cultivation

DNA-free Taq Polymerases and Mastermixes by Molzym
DNA-free reagents for unrivalled sensitivity in molecular biology
Purity that makes the difference

Greener Alternative Products by Merck
Sustainable laboratory products for environmentally conscious research
Over 2,500 ecological alternatives to reduce your laboratory footprint

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.